A First-In-Human Study of LY3985297 in Healthy Participants
Completed · Phase 1 · NCT06395012
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $310,337
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 140
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3985297 (drug), Placebo (drug)
- Dates
- Started 2024-06-07; completion 2025-08-06
- Results posted
- Not yet
The main purpose of this study is to see if LY3985297, the study drug, is safe and well-tolerated when given as a single dose or as multiple doses either through an intravenous (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study will also evaluate how much of the study drug LY3985297 gets into the blood stream and how long it takes the body to remove it. The study is conducted in two parts (part A and B), each part has a separate treatment cohort. The study will last up to approximately 116 days for part A, and 145 days for part B, including the screening period.
From ClinicalTrials.gov, last updated 2025-09-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $310,337 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Peter J. Winkle, MD Gastroenterology · Cypress, CA
- Ahad A. Sabet, M.D. Internal Medicine · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Anaheim Clinical Trials LLC $286,130
- Icon Early Phase Services $24,207
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.